Associations - CTNNB1 (Catenin (cadherin-associated protein), beta 1)

CTNNB1 mutation	Colorectal Cancer	CTNNB1 mutation	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	SM04690 Sensitive: B - Late Trials SM04690 Sensitive : B	SM04690 Sensitive: B - Late Trials SM04690 Sensitive : B
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	everolimus + letrozole Sensitive: C3 – Early Trials everolimus + letrozole Sensitive : C3	everolimus + letrozole Sensitive: C3 – Early Trials everolimus + letrozole Sensitive : C3
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
CTNNB1 mutation	Non Small Cell Lung Cancer	CTNNB1 mutation	Non Small Cell Lung Cancer	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
CTNNB1 mutation	Hepatocellular Cancer	CTNNB1 mutation	Hepatocellular Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CTNNB1 mutation	Hepatocellular Cancer	CTNNB1 mutation	Hepatocellular Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	osimertinib + gefitinib Resistant: C4 – Case Studies osimertinib + gefitinib Resistant : C4	osimertinib + gefitinib Resistant: C4 – Case Studies osimertinib + gefitinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	bevacizumab + osimertinib Resistant: C4 – Case Studies bevacizumab + osimertinib Resistant : C4	bevacizumab + osimertinib Resistant: C4 – Case Studies bevacizumab + osimertinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4

CTNNB1 (Catenin (cadherin-associated protein), beta 1)

Associations(18)

Associations
(18)